<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247074</url>
  </required_header>
  <id_info>
    <org_study_id>43QM1902</org_study_id>
    <nct_id>NCT04247074</nct_id>
  </id_info>
  <brief_title>Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination</brief_title>
  <acronym>READY-3</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for
      the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with a ≥ 2-grade improvement from baseline on the Glabellar Lines Investigator and Subject assessments at maximum frown at one month</measure>
    <time_frame>Month 1</time_frame>
    <description>The investigator and subject evaluate the subject's GL severity using a 4-grade scale (0 = none and 3 = severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with a ≥ 2-grade improvement from baseline on the Lateral Canthal Line Investigator and subject assessments at maximum smile at one month</measure>
    <time_frame>Month 1</time_frame>
    <description>The investigator and subject evaluate the subject's LCL severity using a 4-grade scale (0 = none and 3 = severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with a 0 or 1 on the Glabellar Lines Investigator scale at maximum frown</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieve grade 0 or 1 in Lateral Canthal Line Investigator scale at maximum smile.</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of subjects who experienced an adverse event</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean change from baseline in vital signs</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with abnormal post-baseline QTcF and QTcB intervals</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with binding neutralizing antibodies</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Glabellar Frown Lines (GL)</condition>
  <condition>Lateral Canthal Lines (LCL)</condition>
  <arm_group>
    <arm_group_label>QM1114-DP in the LCL + Placebo in the GL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in the LCL and GL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A buffered solution; Mode of administration:
intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in the LCL + QM1114-DP in the GL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QM1114-DP in the LCL + GL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin neuromodulator</intervention_name>
    <description>QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL</description>
    <arm_group_label>Placebo in the LCL + QM1114-DP in the GL</arm_group_label>
    <arm_group_label>QM1114-DP in the LCL + GL</arm_group_label>
    <arm_group_label>QM1114-DP in the LCL + Placebo in the GL</arm_group_label>
    <other_name>QM1114-DP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be injected into either the LCL, GL, or both the LCL and GL</description>
    <arm_group_label>Placebo in the LCL + QM1114-DP in the GL</arm_group_label>
    <arm_group_label>Placebo in the LCL and GL</arm_group_label>
    <arm_group_label>QM1114-DP in the LCL + Placebo in the GL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 18 years of age or older.

          2. Moderate to severe LCL at maximum smile as assessed by the Investigator.

          3. Moderate to severe LCL at maximum smile as assessed by the subject.

          4. Moderate to severe GL at maximum frown as assessed by the Investigator.

          5. Moderate to severe GL at maximum frown as assessed by the subject

        Exclusion Criteria:

          1. Previous use of any Botulinum toxin in facial areas within 9 months prior to study
             treatment.

          2. Female who is pregnant, breast feeding, or intends to conceive a child during the
             study.

          3. Known allergy or hypersensitivity to any component of the investigational product
             (QM1114-DP).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Galderma Aesthetics</last_name>
    <phone>817-961-5655</phone>
    <email>aestheticclinicaltrials@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Testing of Beverly Hills</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>747-998-5160</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ava MD</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>310-828-2282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skin Care &amp; Laser Physicians of Beverly Hills</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>310-246-0495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baumann Cosmetic &amp; Research Institute, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>305-531-5788</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington Institute of Dermatologic Laser Surgery</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>240-394-8385</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maryland Dermatology, Laser, Skin &amp; Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>410-666-2839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>402-697-6599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lorenc Aesthetic Plastic Surgery Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>212-472-2900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Westlake Dermatology Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>512-615-3180</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bertucci Medspa, Inc</name>
      <address>
        <city>Woodbridge</city>
        <state>Ontario</state>
        <zip>L4L 8E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Clinic</last_name>
      <phone>905-850-4415</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Neurotransmitter Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

